File No. CT/156/22-DCG (I)

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

सत्यमेव जयते

File No. CT/22/000156

To,

M/s Johnson and Johnson Private Limited,
L.B.S. Marg, Mulund West, Maharashtra (India) – 400080.

Sir,

With reference to your application No. GCT/CT04/FF/2022/34990 (GCT/156/22) dated 01-12-2022, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, "**A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancers-Part 5", Protocol Number: 63723283LUC1001; Amendment 6 dated 31-August-2022 with a total of up-to 64 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) The firm and the PI/site should report all the SAEs (death due to PD) to CLA/CDSCO as prescribed under NDCT Rules, 2019;

(ii) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(iii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iv) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(v) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(vi) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vii) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(viii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(ix) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(x) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(xi) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(xii) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiv) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xvi) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvii) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xviii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xix) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

(xx) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=DRUGS CONTROLLER GENERAL (INDIA) D CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI, postalCode=600032, st=TAMILNADU, serialNumber=9...FE73CFA12A1A126EA94EA5701124A19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.03.28 14:21:24 +05'30'

Stamp

File No. CT/156/22-DCG (I)

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s. Johnson & Johnson Pvt. Ltd., L.B.S. Marg, Mulund (W) Mumbai (India) – 400080 Telephone No.: 0124-4647000 FAX: 0124-4647000 E-Mail : RA-JNJIN-REGJJMI@ITS.JNJ.COM** to conduct clinical trial of the new drug or investigational new drug as per **Protocol Number: 63723283LUC1001; Amendment 6 dated 31-August-2022** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DR RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=80c6276a23d4ecfbe8e1392774cdeb03c2760947013a0c664f6679407c05d012b, postalCode=600034, st=TAMIL NADU, serialNumber=6517E4A7A1A0138D4FB3DC902D0E1FE73CFA12A1A126EA94FA5701124A19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.03.28 14:21:38 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority

Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:
Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Cetrelimab
Therapeutic class:	Monoclonal Antibody
Dosage form:	Prefilled Syringe, Solution for infusion in Vials
Composition:	Cetrelimab = 300.0000 mg/2ml in House Specification Active Cetrelimab = 360.0000 mg/vial (12 ml) in House Specification Active
Indications:	Advanced Cancer, unresectable Stage III and Stage IV melanoma

File No. CT/156/22-DCG (I)

Annexure:

Details of clinical trial site:

Names and address of clinical trial site	Ethics committee details	Name of investigator
Department of Medical Oncology, Christian Medical College, CMC Ranipet Campus, Kilminnal, Melvisharam-632517, TamilNadu, India	Institutional Review Board, office of Research, Carman Block, First Floor, Christian Medical College, Bagayam, Vellore -632012,TamilNadu,India ECR/326/Inst/TN/2013/RR-19	Dr. Ashish Singh
Kidwai Memorial Institute of Oncology, DR M H Marigowda Road Bangalore - 560029	Kidwai Memorial Institute of Oncology-IEC, Kidwai Memorial Institute of Oncology, Dr M H Marigowda Road, Hombegowda Nagar, Bengaluru 560029 Karnataka, India ECR/304/Inst/KA/2013/RR-21	Dr. Linu Abraham Jacob
Department of Medical Oncology, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad-50082, Telangana, India	NIMS-Institutional Ethics Committee (NIEC), SRC, 2nd Floor, Old Building, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad-50082, Telangana, India ECR/303/Inst/AP/2013/RR-19	Dr. Sadashivudu Gundeti
Tata Memorial Centre, Dr. E Borges Road, Parel, Mumbai-400012, Maharashtra	Institutional Ethics Committee,3rd Floor, Main Building, Tata Memorial Hospital, Dr. E Borges Road, Parel, Mumbai-400012, Maharashtra ECR/170/Inst/MH/2013/RR-22	Dr. Jyoti Bajpai
Artemis Hospital, Sector-51, Gurugram-122001, Haryana, India	Artemis Health Sciences Institutional Ethics Committee, Artemis Hospital, Sector-51, Gurugram-122001, Haryana, India ECR/53/Inst/HR/2013/RR-19	Dr. Vineet Govinda Gupta
Deenanath Mangeshkar Hospital and Research Center, Erandwane Pune	Institutional Ethics Committee, l4th floor Super Speciality Building Deenanath Mangeshkar Hospital & Research Centre, Erandwane Pune-411004 ECR/15/Inst/Maha/2013/RR-22	Dr. Chetan Dilip Deshmukh
Department of Surgical Oncology, Shatabdi Phase 2, 3rd Floor, King George's Medical University, Chowk, Lucknow - 226003, Uttar Pradesh. India	Institutional Ethics Committee, Office of Research Cell, King George Medical University, Lucknow - 226003, Uttar Pradesh, India ECR/262/Inst/UP/2013/RR-16	Dr. Naseem Akhtar

File No. CT/156/22-DCG (I)

AIIMS (All India Institute of Medical Sciences) Room No. 243, IRCH Building, Ansari Nagar, Delhi-110029	Institute Ethics Committee (AIIMS), Room no. 102, First Floor, Old OT Block, AIIMS, Ansari Nagar, New Delhi-110029 ECR/New/Inst/2022/DL/0144	Dr. Sameer Bakhshi
Surat Institute of Digestive Sciences (SIDS), SIDS Hospital and Research Centre, A unit of SIDS Healthcare Pvt. Ltd., JJ Empire Building & Tapi Villa Building, Vijay Nagar Gate No. 3, Beside Nirman Bhavan, Opposite Gandhi College, Near Dayalji Ashram, Majura Gate , Ring Road, Surat-395002, Gujarat, India	Surat Institute of Digestive Sciences Ethics Committee, Surat Institute of Digestive Sciences, Vijay Nagar Gate No. 3, Besides Nirman Bhavan, Opposite Gandhi College, Majura Gate , Ring Road, Surat-395002, Gujarat, India ECR/813/Inst/GJ/2016/RR-19	Dr. Dhruv Pankaj Mehta
Srinivasam Cancer Care Multispeciality Hospital, 1st A Main Road, 5th Cross Road, 36, Netravati St. Maruthi Nagar, Bengaluru, Karnataka-560072	Srinivasam Cancer Care Multispeciality Hospital- Institutional Ethics Committee, #36,1st-A Main, 5th Cross (Nethravathi Street), Maruthinagar, Nagarbhavi Main Road, Bangalore - 560072 ECR/193/Inst/KA/2013/RR-20	Dr. K.C. Lakshmaiah
Dept. of Medical Oncology, Institute of Medical Sciences (IMS) & SUM Hospital, S 'O' A Deemed to be University, K-8, Kalinga Nagar, Ghatikia, Khandagiri, Bhubaneswar, Odisha-75 1003, India	Institutional Ethics Committee, IMS & SUM Hospital, Institute of Medical Sciences (IMS) & SUM Hospital, S 'O' A Deemed to be University, K-8, Kalinga Nagar, Ghatikia, Khandagiri, Bhubaneswar, Odisha-751003, India ECR/627/Inst/OR/2014/RR-20	Dr. Soumya Surath Panda
Sanjeevani CBCC USA Cancer Hospital, In Front of Jain Mandir, Dawada Colony Pachpedi Naka Raipur, 492001 Chhattisgarh	Sanjeevani CBCC USA Cancer Hospital Institutional Ethics Committee, Sanjeevani CBCC USA Cancer Hospital, In Front of Jain Mandir, Dawada Colony Pachpedi Naka Raipur, 492001 Chhattisgarh ECR/818/Inst/CG/2016/RR-19	Dr. Aniket Thoke

****